Table 3.
Prevalence of the 4 TCGA molecular prognostic groups across different histotypes of endometrial carcinoma.
| Molecular Prognostic Group | LG-EEC | HG-EEC | SC | CCC | Mixed | UDC/ DDC |
CS | NEC *** | MLC |
|---|---|---|---|---|---|---|---|---|---|
| POLE-mutated | 6.2% | 12.1% | 0% * | 3.8% | 5.6% | 12.4% | 5.3% | 7.1% | 0% |
| MMR-deficient | 24.7% | 39.7% | 0% * | 9.8% | 33.3% | 44% | 7.3% | 42.9% | 0% |
| p53-abnormal | 4.7% | 21.3% | 100% ** | 42.5% | 61.1% | 18.6% | 73.9% | 35.7% | 0% |
| NSMP | 63.5% | 28% | 0% * | 40.9% | 0% | 25% | 13.5% | 14.3% | 100% |
LG-EEC: low-grade endometrioid carcinoma; HG-EEC: high-grade endometrioid carcinoma; SC: serous carcinoma; CCC: clear-cell carcinoma; Mixed: mixed carcinoma; UDC/DDC: undifferentiated/dedifferentiated carcinoma; CS: carcinosarcoma; NEC: neuroendocrine carcinoma; MLC: mesonephric-like carcinoma. * Endometrial carcinomas with a serous morphology and POLE mutation or MMR deficiency are diagnosed as serous-like high-grade endometrioid carcinoma. ** Serous carcinomas with normal p53 expression in the presence of TP53 mutation, or with no TP53 mutation but with high copy-number variation, may rarely occur. *** The only published series of endometrial neuroendocrine carcinoma assessed with the TCGA classifier was constituted of 4 pure neuroendocrine carcinomas and 10 mixed carcinomas with a neuroendocrine component [30].